New therapeutic developments in renal cell cancer

被引：4

作者：

Prenen, Hans ^{[1
,2
]}

Gil, Thierry ^{[2
]}

Awada, Ahmad ^{[2
]}

机构：

[1] Catholic Univ Louvain, Univ Hosp Gasthuisberg, Dept Gen Med Oncol, B-3000 Louvain, Belgium

[2] Inst Jules Bordet, Dept Med, Med Oncol Clin, B-1000 Brussels, Belgium

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2009年 / 69卷 / 01期

关键词：

Renal cell cancer; Molecular targeted therapy; Angiogenesis; Sunitinib; Sorafenib; Temsirolimus; ENDOTHELIAL GROWTH-FACTOR; RANDOMIZED DISCONTINUATION TRIAL; RADICAL NEPHRECTOMY; INTERFERON-ALPHA; PHASE-II; ANTITUMOR-ACTIVITY; TUMOR PROGRESSION; KINASE INHIBITOR; CARCINOMA; INTERLEUKIN-2;

D O I：

10.1016/j.critrevonc.2008.07.007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Metastatic renal cell cancer is associated with a poor prognosis and is very resistant to conventional cytotoxic chemotherapy. Progress in the understanding of molecular biology and pathogenesis of renal cell cancer has been translated into the development of new therapeutic strategies. The recent approval Of sunitinib, sorafenib, temsirolimus and bevacizumab in combination with IFN-alpha has revolutionized the management of renal cell carcinoma. In this review, we describe the status of current treatment strategies for metastatic renal cell cancer and We focus Oil the new compounds including targeted therapy such as new anti-angiogenic and mTOR inhibitors. (c) 2008 Elsevier Ireland Ltd. All rights reserved.

引用

页码：56 / 63

页数：8

共 57 条

[11] RESULTS OF TREATMENT OF 255 PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA WHO RECEIVED HIGH-DOSE RECOMBINANT INTERLEUKIN-2 THERAPY [J].

FYFE, G ;

FISHER, RI ;

ROSENBERG, SA ;

SZNOL, M ;

PARKINSON, DR ;

LOUIE, AC .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (03) :688-696

[12] Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma [J].

Han, KR ;

Pantuck, AJ ;

Bui, MHT ;

Shvarts, O ;

Freitas, DG ;

Zisman, A ;

Leibovich, BC ;

Dorey, FJ ;

Gitlitz, BJ ;

Figlin, RA ;

Belldegrun, AS .

UROLOGY, 2003, 61 (02) :314-319

[13]

Houk BE, 2007, J CLIN ONCOL, V25

[14] Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma [J].

Hudes, Gary ;

Carducci, Michael ;

Tomczak, Piotr ;

Dutcher, Janice ;

Figlin, Robert ;

Kapoor, Anil ;

Staroslawska, Elzbieta ;

Sosman, Jeffrey ;

McDermott, David ;

Bodrogi, Istvan ;

Kovacevic, Zoran ;

Lesovoy, Vladimir ;

Schmidt-Wolf, Ingo G. H. ;

Barbarash, Olga ;

Gokmen, Erhan ;

O'Toole, Timothy ;

Lustgarten, Stephanie ;

Moore, Laurence ;

Motzer, Robert J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (22) :2271-2281

[15]

Hutson TE, 2007, J CLIN ONCOL, V25

[16]

Jac J, 2007, J CLIN ONCOL, V25

[17]

JAC J, 2008, P AM SOC CLIN ONCOL

[18] Prognostic significance of the 1997 TNM classification of renal cell carcinoma [J].

Javidan, J ;

Stricker, HJ ;

Tamboli, P ;

Amin, MB ;

Peabody, JO ;

Deshpande, A ;

Menon, M ;

Amin, MB .

JOURNAL OF UROLOGY, 1999, 162 (04) :1277-1281

[19] Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial [J].

Jocham, D ;

Richter, A ;

Hoffmann, L ;

Iwig, K ;

Fahlenkamp, D ;

Zakrzewski, G ;

Schmitt, E ;

Dannenberg, T ;

Lehmacher, W ;

von Wietersheim, J ;

Doehn, C .

LANCET, 2004, 363 (9409) :594-599

[20] Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings [J].

Jonasch, E. ;

Wood, C. ;

Tamboli, P. ;

Pagliaro, L. C. ;

Tu, S. M. ;

Kim, J. ;

Srivastava, P. ;

Perez, C. ;

Isakov, L. ;

Tannir, N. .

BRITISH JOURNAL OF CANCER, 2008, 98 (08) :1336-1341

← 1 2 3 4 5 6 →